Adaptive Biotechnologies (ADPT) Set to Announce Earnings on Tuesday

Adaptive Biotechnologies (NASDAQ:ADPT) is set to release its earnings data after the market closes on Tuesday, May 7th. Analysts expect Adaptive Biotechnologies to post earnings of ($0.35) per share for the quarter. Persons that are interested in registering for the company’s earnings conference call can do so using this link.

Adaptive Biotechnologies (NASDAQ:ADPT) last released its quarterly earnings data on Wednesday, February 14th. The company reported ($0.30) EPS for the quarter, beating analysts’ consensus estimates of ($0.32) by $0.02. The business had revenue of $45.78 million during the quarter, compared to the consensus estimate of $50.15 million. Adaptive Biotechnologies had a negative return on equity of 53.65% and a negative net margin of 132.29%. On average, analysts expect Adaptive Biotechnologies to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Adaptive Biotechnologies Trading Up 2.7 %

Adaptive Biotechnologies stock opened at $3.01 on Friday. The firm has a market capitalization of $443.58 million, a P/E ratio of -1.93 and a beta of 1.27. The business has a 50-day moving average of $3.12 and a 200-day moving average of $3.92. Adaptive Biotechnologies has a 1 year low of $2.28 and a 1 year high of $9.08.

Insider Buying and Selling at Adaptive Biotechnologies

In other news, SVP Stacy L. Taylor sold 13,381 shares of the stock in a transaction on Tuesday, March 5th. The shares were sold at an average price of $3.43, for a total transaction of $45,896.83. Following the completion of the sale, the senior vice president now owns 166,287 shares of the company’s stock, valued at $570,364.41. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, SVP Stacy L. Taylor sold 13,381 shares of the business’s stock in a transaction dated Tuesday, March 5th. The stock was sold at an average price of $3.43, for a total value of $45,896.83. Following the sale, the senior vice president now directly owns 166,287 shares in the company, valued at $570,364.41. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, President Julie Rubinstein sold 39,070 shares of the stock in a transaction dated Tuesday, March 5th. The stock was sold at an average price of $3.47, for a total value of $135,572.90. Following the transaction, the president now owns 472,754 shares of the company’s stock, valued at $1,640,456.38. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 124,307 shares of company stock valued at $428,090. 5.20% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on ADPT shares. JPMorgan Chase & Co. decreased their price objective on shares of Adaptive Biotechnologies from $11.00 to $8.00 and set an “overweight” rating for the company in a report on Thursday, February 15th. The Goldman Sachs Group decreased their price target on shares of Adaptive Biotechnologies from $11.00 to $5.00 and set a “neutral” rating for the company in a report on Friday, February 16th. Finally, BTIG Research dropped their price objective on Adaptive Biotechnologies from $6.00 to $5.00 and set a “buy” rating on the stock in a research note on Thursday, April 4th. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $6.80.

About Adaptive Biotechnologies

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system.